𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

✍ Scribed by Peter Hersey; ScottW. Menzies; GaryM. Halliday; Tam Nguyen; MargaretL. Farrelly; Chitra DeSilva; Margaret Lett

Publisher
Springer-Verlag
Year
2004
Tongue
English
Weight
214 KB
Volume
53
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I study in melanoma patients of a
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
✍ Andreas Mackensen; Birgit Herbst; Ji-Li Chen; Gabriele KΓΆhler; Christoph Noppen; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 268 KB πŸ‘ 2 views

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that can be used for vaccination purposes, to induce a specific T-cell response in vivo against melanomaassociated antigens. We have shown that the sequential use of early-acting hematopoietic growth factors, stem cell factor, IL

Phase II study of high-dose tamoxifen (N
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
✍ Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 3 views

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reas